Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019
Cited by 1,660 works. doi:10.1016/s1470-2045(19)30167-6
Authors
- Howard West
- Michael McCleod
- Maen Hussein
- Alessandro Morabito
- Achim Rittmeyer
- Henry Jacob Conter
- Hans‐Georg Kopp
- Davey B. Daniel
- Steven L. McCune
- Tarek M. Mekhail
- Alona Zer
- Niels Reinmuth
- Ahad Ali Sadiq
- Alan Sandler
- Wei Y. Lin
- Tania Ochi Lohmann
- Venice Rosalie Archer
- Lijia Wang
- Marcin Kowanetz
- Federico Cappuzzo
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- A Confidence Interval for the Median Survival Time
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer